Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$17M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 154%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash of $78000 is below short-term debt of $6M — relies on refinancing/operations.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-08-04
Where each multiple sits in its own 6-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 6-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2017 | FY2018 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 67.5 | 58.0 | 467.6 | — | 103.2 | 14.8 | 1180.2 | 186.3 |
| Gross Profit | 32.5 | 42.0 | — | — | — | 88.9 | -1080.2 | -86.3 |
| R&D | 24.6 | 34.7 | 359.4 | 1097.6 | 103.2 | 63.1 | 2004.3 | 929.7 |
| SG&A | 91.1 | 87.4 | 293.7 | 247.9 | 41.4 | 44.9 | 6629.1 | 1432.1 |
| Operating Income | -111.3 | -74.6 | 563.6 | -1251.8 | -47.3 | -29.1 | -10120.0 | -3842.3 |
| Income Tax | -13.0 | 7.2 | 5.9 | -21.0 | 0.3 | 0.6 | 89.2 | 9.4 |
| Net Income | -122.6 | -98.0 | 618.6 | 14.5 | -50.9 | -42.9 | -10445.5 | -4653.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ORGS: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-08-04 · 16d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M 100.0% | $530K 100.0% | $34.7M 100.0% | $35.5M 100.0% | $7.7M 100.0% | $3.9M 100.0% | $18.7M 100.0% | $10.1M 100.0% | $6.4M 100.0% | $3.0M 100.0% |
| Cost of Revenue | $1.9M 186.3% | $6.3M 1180.2% | $5.1M 14.8% | $36.6M 103.2% | — | $18.2M 467.6% | $10.8M 58.0% | $6.8M 67.5% | $7.7M 119.7% | $3.9M 130.5% |
| Gross Profit | -$893K -86.3% | -$5.7M -1080.2% | $30.9M 88.9% | — | — | — | $7.8M 42.0% | $3.3M 32.5% | -$1.3M -19.7% | -$906K -30.5% |
| Research & Development | $9.6M 929.7% | $10.6M 2004.3% | $21.9M 63.1% | $36.6M 103.2% | $84.0M 1097.6% | $14.0M 359.4% | $6.5M 34.7% | $2.5M 24.6% | $2.2M 33.7% | $1.1M 35.9% |
| Selling, General & Admin | $14.8M 1432.1% | $35.1M 6629.1% | $15.6M 44.9% | $14.7M 41.4% | $19.0M 247.9% | $11.5M 293.7% | $16.3M 87.4% | $9.2M 91.1% | $6.2M 97.5% | $4.0M 135.7% |
| Operating Income | -$39.8M -3842.3% | -$53.6M -10120.0% | -$10.1M -29.1% | -$16.8M -47.3% | -$95.8M -1251.8% | $22.0M 563.6% | -$13.9M -74.6% | -$11.2M -111.3% | -$11.4M -178.2% | -$7.2M -242.5% |
| Other Income (Expense), net | -$4.5M -435.6% | -$2.5M -471.5% | -$2.0M -5.7% | -$1.3M -3.6% | -$1.1M -13.9% | $843K 21.6% | -$3.1M -16.7% | -$2.4M -24.3% | -$1.3M -19.7% | $1.9M 62.2% |
| Pretax Income | -$48.9M -4726.2% | -$64.4M -12159.4% | -$12.0M -34.4% | -$18.0M -50.6% | -$96.7M -1264.2% | $22.8M 585.2% | -$17.8M -95.2% | -$13.7M -135.6% | -$12.7M -197.9% | -$5.4M -180.3% |
| Income Tax Expense | $97K 9.4% | $473K 89.2% | $209K 0.6% | $108K 0.3% | -$1.6M -21.0% | $229K 5.9% | $1.3M 7.2% | -$1.3M -13.0% | -$1.5M -24.2% | -$900K -30.3% |
| Net Income | -$48.2M -4653.6% | -$55.4M -10445.5% | -$14.9M -42.9% | -$18.1M -50.9% | $1.1M 14.5% | $24.1M 618.6% | -$18.3M -98.0% | -$12.4M -122.6% | -$11.1M -173.7% | -$4.5M -150.0% |
| Per Share | ||||||||||
| EPS (Basic) | $11.44 | $19.08 | $0.59 | $0.74 | $-0.29 | $1.77 | $-1.43 | $-1.28 | $1.30 | $0.08 |
| EPS (Diluted) | $11.44 | $19.08 | $0.59 | — | — | $-1.77 | $-1.43 | $-1.31 | $1.30 | $0.11 |
| Weighted Avg Shares (Basic) | 4.2M | 2.9M | 25.1M | 24.3M | — | 15.9M | 13.4M | 9.7M | 8.5M | 55.8M |
| Weighted Avg Shares (Diluted) | 4.2M | 2.9M | 25.1M | — | — | 15.9M | 13.4M | 9.7M | 8.5M | 56.9M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| ORGS | $2M | 0.0× | — | 2.0× | 95.3% | -86.3% | -4654% | 128% | 154% | -0.2× | 1 |
Peers = companies sharing ORGS's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.